Tumor News and Research

RSS

Eribulin from marine sponge inhibits replication of breast cancer cells

For more than three decades a new drug for the treatment of breast cancer had not been presented. A group of researchers were given the task of analyzing a marine sponge called Halichondrin okadai and obtained a mesylate eribulin substance that had already been applied to patients with this disease in the stage of metastasis, ie, when the disease spreads to other body parts and the result was that it inhibited tumor growth.

4 May 2015

No evidence for cancer risk with growth hormone therapy

There is no evidence that growth hormone (GH) therapy increases the likelihood of neoplasms in children with no additional risk factors, says the Pediatric Endocrine Society Drug and Therapeutics Committee.

1 May 2015

DelMar to present new data on development of VAL-083 at 2015 ASCO Annual Meeting

DelMar Pharmaceuticals, Inc., today announced that it will be presenting new data related to the development of lead product candidate VAL-083 (dianhydrogalactitol) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2, 2015, in Chicago, Illinois.

30 Apr 2015

OncoGenex provides update on Phase 3 ENSPIRIT trial evaluating custirsen for treatment of NSCLC

OncoGenex Pharmaceuticals, Inc. announced today it has filed an amendment with the U.S. Food and Drug Administration, as well as initiated filing with regulatory agencies in other countries, to amend the statistical design and analysis plan of its pivotal, international Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC).

30 Apr 2015

ITIM-containing receptor crucial for development of acute myeloid leukemia

UT Southwestern Medical Center scientists have discovered that a certain class of receptors that inhibit immune response are crucial for the development of acute myeloid leukemia (AML), the most common acute leukemia affecting adults.

30 Apr 2015

Novel combination therapy shows promise in mouse models of advanced prostate cancer

Chemotherapy can be very effective against small prostate tumors. Larger prostate tumors, however, accumulate cells that suppress the body's immune response, allowing the cancer to grow despite treatment.

30 Apr 2015

Long-term survivors of esophageal cancer still face continued risks, study finds

Patients with esophageal cancer who survive 5 years after undergoing surgery might breathe a sigh of relief and become complacent about continued monitoring. In fact, there is little published information on the outcome of patients with locally advanced esophageal cancer (LAEC) who survive beyond the 5-year mark.

30 Apr 2015

Research provides insights into the ability of FL118 to overcome treatment resistance

The latest research from the team that discovered the novel anticancer agent FL118 highlights distinctive characteristics of this small-molecule compound and provides insights into its ability to overcome the persistent problem of treatment resistance. In findings reported in Molecular Cancer, Fengzhi Li, PhD, of Roswell Park Cancer Institute, and colleagues provide new evidence that FL118 may be more effective than two structurally similar injectable drugs and, additionally, may be effective as an oral agent.

30 Apr 2015

Study opens door for new therapeutic approaches to treating patients with melanoma

Weill Cornell Medical College researchers have shown for the first time that a gene previously implicated in blood vessel formation during embryonic development and tumor growth also induces immune suppression during tumor development.

30 Apr 2015

CANCER-ID consortium aims to set up standard procedures for clinical validation of blood-based biomarkers

Blood-based biomarkers such as circulating tumor cells (CTCs), circulating free DNA (cfDNA), circulating tumor DNA (ctDNA) and microRNAs (miRNAs) are potential indicators for the tumor burden of patients living with cancer.

30 Apr 2015

Oncologists need to screen tumor patients for depression

Because depression in brain cancer patients is a common but often overlooked condition, oncologists should regularly screen tumor patients for depression, according to an article in the current issue of CNS Oncology. The journal is published by Future Medicine, an imprint of Future Science Group.

30 Apr 2015

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Sangamo BioSciences, Inc. announced that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics will be presented at the 18th Annual Meeting of the American Society of Gene and Cell Therapy

29 Apr 2015

Researchers describe critical connection associated with environmental cause of silicosis, lung cancer

Researchers at the University of Louisville have detailed a critical connection associated with a major environmental cause of silicosis and a form of lung cancer. Their study is reported in today's Nature Communications.

29 Apr 2015

McMaster researchers explore how surgeon's experience influences choice of surgery for patients

Researchers at McMaster University (Hamilton, ON) explored whether a surgeon's expertise influences procedural choice. The results of a new study of more than 8000 non-small cell lung cancer (NSCLC) patients undergoing surgical resection by 124 physicians showed that surgeons who perform more surgeries are less likely to perform high-risk pneumonectomies. Christian J. Finley, MD, MPH, will be presenting the results of this research at the 95th AATS Annual Meeting in Seattle, WA on April 28, 2015.

29 Apr 2015

Scientists reveal complex role of soy in preventing and advancing breast cancer

Scientists have mapped the human genes triggered by the phytonutrients in soy, revealing the complex role the legume plays in both preventing and advancing breast cancer.

29 Apr 2015

PCDx test performs better than FoundationOne test in clinical study

Data from a small cohort published OncoTargets and Therapy today shows that the Paradigm Cancer Diagnostic Test (PCDx) performed better than Foundation Medicine's FoundationOne test across a number of key clinical variables, including turnaround time (TAT) and clinically actionable biomarker targets.

28 Apr 2015

Researchers identify molecular switch for protein that causes HER2-positive breast cancer

Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein. However, not all of these patients respond to the drug, and many who do respond eventually acquire resistance.

28 Apr 2015

Molecular Health granted European patent for novel Erythropoietin receptor

Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.

27 Apr 2015

OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers.

27 Apr 2015

Humanized mouse model may lead to better anti-cancer therapies

Human tumors grown in mouse models have long been used to test promising anti-cancer therapies. However, when a human tumor is transplanted into a mouse, the mouse immune system must be knocked down so that it doesn't attack the foreign tumor tissue, thus allowing the tumor to grow.

27 Apr 2015

Tumor News and Research

Eribulin from marine sponge inhibits replication of breast cancer cells

No evidence for cancer risk with growth hormone therapy

DelMar to present new data on development of VAL-083 at 2015 ASCO Annual Meeting

OncoGenex provides update on Phase 3 ENSPIRIT trial evaluating custirsen for treatment of NSCLC

ITIM-containing receptor crucial for development of acute myeloid leukemia

Novel combination therapy shows promise in mouse models of advanced prostate cancer

Long-term survivors of esophageal cancer still face continued risks, study finds

Research provides insights into the ability of FL118 to overcome treatment resistance

Study opens door for new therapeutic approaches to treating patients with melanoma

CANCER-ID consortium aims to set up standard procedures for clinical validation of blood-based biomarkers

Oncologists need to screen tumor patients for depression

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Researchers describe critical connection associated with environmental cause of silicosis, lung cancer

McMaster researchers explore how surgeon's experience influences choice of surgery for patients

Scientists reveal complex role of soy in preventing and advancing breast cancer

PCDx test performs better than FoundationOne test in clinical study

Researchers identify molecular switch for protein that causes HER2-positive breast cancer

Molecular Health granted European patent for novel Erythropoietin receptor

OncoGenex terminates agreement with Teva, regains rights to custirsen

Humanized mouse model may lead to better anti-cancer therapies

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News